Brasília – Brazilian pharmaceutical company Eurofarma and Danish multinational Novo Nordisk have established a strategic partnership to expand the distribution of semaglutide-based injectable products in Brazil.

Under the agreement, Eurofarma will be responsible for the distribution and promotion of two new brands: Poviztra, indicated for the treatment of obesity and overweight with associated comorbidities, and Extensior, aimed at patients with type 2 diabetes.

The collaboration seeks to broaden access to innovative therapies and strengthen supply across Brazil, reaching regions and healthcare providers not currently covered by Novo Nordisk. According to Allan Finkel, vice president for Latin America and Brazil, the initiative reflects the company’s goal of expanding access to advanced treatments while maintaining high standards of quality and safety.

Renata Campos, president of Eurofarma in Brazil, emphasized that the company’s strong commercial presence and distribution capacity will help ensure that more patients benefit from these therapies, reinforcing Eurofarma’s commitment to innovation and public health.

Source: CNN Brasil

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com